Dorton Katina reported grant involving 67,000 derivative units of TScan Therapeutics, Inc. at $0.00 for $0 on May 20, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
67,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
67,000Direct
Trade date
May 20, 2026Grant
Filed
May 22, 2026, 4:05 PM ET2-day reporting delay
Accession
0001193125-26-236844Code A · Transaction 383529
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TCRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TCRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +35%1w ago +9.4%1d ago −9.4%
Returns since7d +1.9%30d −13%90d −26%180d1y

Footnotes in full

F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.